Wegovy is a registered trademark of Novo Nordisk A/S. Medicare coverage depends on the prescribed use, the member's Part D benefit, current plan rules, and whether a separate CMS program applies.
Important safety information: Wegovy has a boxed warning about the risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Serious risks include pancreatitis, gallbladder problems, low blood sugar, acute kidney injury, severe gastrointestinal reactions, serious allergic reactions, diabetic retinopathy complications, and increased heart rate. Review the complete official Wegovy Prescribing Information and Medication Guide with a licensed clinician.
This page is general information, not medical advice. Talk to a licensed clinician about your situation.
Part D coverage depends on the use
Federal law has historically excluded drugs used for weight loss from the basic Medicare Part D benefit. A medicine with multiple FDA-approved uses may still be coverable when prescribed for another use that Part D can cover.
The FDA label includes use of Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. CMS guidance identifies this cardiovascular use as coverable under Part D, subject to the plan's benefit rules and review.
The current FDA label also contains other indications. Coverage analysis must use the actual prescribed use and the member's current plan documents. A person should not assume that approval for one use establishes coverage for another.
The Medicare GLP-1 Bridge in 2026
CMS launched the Medicare GLP-1 Bridge on July 1, 2026. It operates outside the standard Part D benefit payment flow and is scheduled through December 31, 2027. It covers specified products for eligible Part D beneficiaries who meet the program's weight-management criteria.
The official CMS information for Part D plans lists current products, clinical criteria, exclusions, cost sharing, and operating dates. CMS states that eligible beneficiaries pay a $50 copay for a monthly supply under the Bridge. That copay does not count toward Part D true out-of-pocket costs.
Bridge eligibility is not automatic. A provider must submit a prior authorization attesting that the beneficiary meets the current criteria. People prescribed Wegovy for a use already coverable under basic Part D, such as the labeled cardiovascular risk-reduction use, are directed through their Part D plan rather than the Bridge.
Start with the Part D plan
Call the number on the Part D card and ask about the exact prescribed use. Ask whether Wegovy is on the formulary, which utilization rules apply, and whether the request should follow ordinary Part D processing or the Bridge process.
Useful questions include:
- Which written coverage criteria apply to this prescribed use?
- Is prior authorization required?
- Which pharmacies are in network or preferred?
- What cost sharing applies after approval?
- If denied, what exception or appeal process is available?
Record the date and call reference number. A representative's estimate can help, but the plan's formal decision and processed pharmacy claim determine the result.
Prior authorization and plan exceptions
Prior authorization allows the plan or Bridge administrator to compare the request with current program criteria. The clinician may need to submit diagnosis information, medical history, and other records. A complete request does not assure approval.
If the Part D plan denies coverage, request the written decision. It should explain the reason and review rights. CMS says the Bridge does not modify Part D appeal rights, including formulary exception requests.
Follow the instructions and deadlines in the notice. Ask the plan which specific requirement was not met. The clinician can address accurate medical documentation, while the plan answers benefit and appeal questions.
Medicare Advantage and dual eligibility
Many Medicare Advantage plans include Part D coverage. In that case, use the prescription benefit information supplied by the plan. The medical and drug portions of the same plan can have different contacts and rules.
People enrolled in both Medicare and Medicaid may have additional cost-sharing support, but coordination varies. The Bridge's $50 copay is outside the Part D payment flow, and CMS says low-income cost-sharing subsidies do not apply to it.
Do not assume Medicaid replaces Part D for a dual-eligible member. Call both programs when coordination is unclear and confirm which pharmacy billing information should be used.
Body Good service fees and support
Body Good may assist with benefit checks and requested authorization paperwork. This is coverage support. It does not guarantee Medicare approval, Bridge eligibility, payment, or a specific copay. The plan or program administrator decides.
Body Good's prices are service fees for the program described during intake. They are not the price of medication and are not a quote for any individual. Eligibility is determined by a clinician. Medication cost is separate and is not included in a Body Good service fee.
This website provides an informational and pricing overview. It does not take payment, collect protected health information, or operate an intake form. Intake and checkout happen on joinbodygood.com.
Frequently asked questions
Does Part D cover Wegovy for cardiovascular risk reduction?
CMS identifies its labeled cardiovascular risk-reduction use as coverable under Part D. The member's plan still applies its formulary, authorization, and other benefit rules, so coverage is not automatic.
Is everyone with Part D eligible for the GLP-1 Bridge?
No. The Bridge has specific clinical and program criteria and requires prior authorization. It is intended for specified weight-management uses that are not otherwise coverable through the basic Part D benefit.
Can Body Good guarantee Medicare approval?
No. Body Good offers coverage support, while the plan or Bridge administrator makes the decision. Begin the secure clinical intake for clinical review.
Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Body Good is not affiliated with, endorsed by, sponsored by, or authorized by Eli Lilly and Company or Novo Nordisk A/S. All trademarks are the property of their respective owners.